Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03), FiscalAI reports. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.34 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%.

Dyadic International Price Performance

DYAI stock traded up $0.03 during mid-day trading on Wednesday, reaching $0.87. 100,793 shares of the company traded hands, compared to its average volume of 60,100. The company has a fifty day moving average price of $0.83 and a 200-day moving average price of $0.95. Dyadic International has a 52-week low of $0.71 and a 52-week high of $1.45. The company has a market capitalization of $31.58 million, a P/E ratio of -3.64 and a beta of 1.29. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Institutional Trading of Dyadic International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter valued at $190,000. Geode Capital Management LLC increased its holdings in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.